-
Mashup Score: 7
Objective To evaluate the 12-month efficacy and safety profile of adalimumab and etanercept in patients with ankylosing spondylitis (AS) and total spinal ankylosis (TSA). Type of study design Case-series follow-up study. Design Twenty-eight patients (26 men and 2 women) with active AS (BASDAI > 4) and TSA were treated as follows: 19 patients receiving adalimumab and 9 patients receiving…
Source: SpringerLinkCategories: Latest Headlines, RheumatologyTweet
-
Mashup Score: 0Etanercept Achieves Treat-to-Target Goals in RA - 2 year(s) ago
In rheumatoid arthritis, a treat-to-target approach aims for remission or low disease activity within the first 3 months. However, investigators noted that improvements continued to increase throughout the 52-week period.
Source: Rheumatology NetworkCategories: Latest Headlines, RheumatologyTweet-
A significant amount of patients with #rheumatoidarthritis were able to achieve low disease activity or remission after 12 weeks of #etanercept treatment, which continued to increase up to week 52. Learn more: https://t.co/61NY9bgz9T
-
-
Mashup Score: 0
Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) are fatal severe cutaneous adverse reactions, without consensus on the medical treatment. The use of systemic corticosteroids or intravenous immunoglobulin (IVIG) remains debatable. Tumor necrosis factor-α (TNF-α) inhibitors are potentially effective.
Categories: Allergy-Immunology, Latest HeadlinesTweet-
In Press! Evaluation of combination therapy with #etanercept and #systemic #corticosteroids for #Stevens- #Johnson #syndrome and #toxic #epidermal #necrolysis: A multicenter observational study https://t.co/1vx45QGfPq
-
-
Mashup Score: 0Enthesitis-related arthritis, family history, etanercept use tied to IBD risk in JIA - 3 year(s) ago
Enthesitis-related arthritis and a family history of autoimmune disease are key risk factors for inflammatory bowel disease in juvenile idiopathic arthritis, according to data published in Rheumatology. The researchers additionally found data linking etanercept (Enbrel, Amgen) to a higher incidence of IBD regardless of whether it is combined with methotrexate.
Source: www.healio.comCategories: Latest Headlines, RheumatologyTweet-
Enthesitis-related #arthritis, family history of #AutoimmuneDisease and #etanercept use were tied to #IBD risk in #JIA https://t.co/P9XnPiSLEv https://t.co/sazE0sNOaw
-
-
Mashup Score: 0Comparing Efficacy and Safety of Etanercept and Biosimilars in Patients With Juvenile Idiopathic Arthritis - 3 year(s) ago
Disease activity, safety, and the occurrence of adverse events were similar in patients with juvenile idiopathic arthritis receiving either etanercept or the biosimilars Benepali and Erelzi.
Source: Rheumatology NetworkCategories: Latest Headlines, RheumatologyTweet-
How does #etanercept compare to #biosimilars in terms of efficacy, safety, and occurrence of adverse events? https://t.co/JiJZq2ABoK
-
-
Mashup Score: 0Methotrexate use varies significantly prior to etanercept in juvenile idiopathic arthritis - 3 year(s) ago
There is significant variation in the patterns of methotrexate use prior to initiating etanercept in patients with juvenile idiopathic arthritis, according to registry data published in Pediatric Rheumatology.“Although etanercept has been approved for the treatment of JIA for more than 20 years, there are knowledge gaps about its contemporary usage patterns that we sought to address using
Source: www.healio.comCategories: Latest Headlines, RheumatologyTweet-
“Although #etanercept has been approved for the treatment of #JIA for more than 20 years, there are knowledge gaps about its contemporary usage patterns...” Dr. Timothy Beukelman told @HealioRheum https://t.co/5tet8q3bKh
-
-
Mashup Score: 0Comparing Efficacy and Safety of Etanercept and Biosimilars in Patients With Juvenile Idiopathic Arthritis - 3 year(s) ago
Disease activity, safety, and the occurrence of adverse events were similar in patients with juvenile idiopathic arthritis receiving either etanercept or the biosimilars Benepali and Erelzi.
Source: Rheumatology NetworkCategories: Latest Headlines, RheumatologyTweet-
Disease activity, safety, and the occurrence of adverse events were similar in patients with juvenile idiopathic arthritis receiving either #etanercept or the biosimilars #Benepali and #Erelzi. https://t.co/JiJZq2ScNk
-
-
Mashup Score: 1Methotrexate use varies significantly prior to etanercept in juvenile idiopathic arthritis - 3 year(s) ago
There is significant variation in the patterns of methotrexate use prior to initiating etanercept in patients with juvenile idiopathic arthritis, according to registry data published in Pediatric Rheumatology.“Although etanercept has been approved for the treatment of JIA for more than 20 years, there are knowledge gaps about its contemporary usage patterns that we sought to address using
Source: www.healio.comCategories: Latest Headlines, RheumatologyTweet-
#Methotrexate use varies significantly prior to #etanercept in juvenile idiopathic #arthritis #JIA https://t.co/5tet8q3bKh https://t.co/0qO6WMJYn4
-
-
Mashup Score: 0Monoclonal TNF inhibitors outperform secukinumab, etanercept for preventing uveitis in SpA - 3 year(s) ago
Secukinumab and etanercept are associated with an increased risk for anterior uveitis in patients with spondyloarthritis, compared with monoclonal TNF inhibitors, according to data published in the Annals of the Rheumatic Diseases.“For [anterior uveitis (AU)], TNF inhibitors reduce the frequency of flares in [axial SpA], and the presence of AU has been linked to a better TNF inhibitors
Source: www.healio.comCategories: Latest Headlines, RheumatologyTweet-
#Secukinumab and #etanercept were associated with an increased risk for anterior #uveitis in patients with #spondyloarthritis when compared with monoclonal TNF inhibitors, according to researchers @uniofgothenburg https://t.co/GIleLwhtvc
-
-
Mashup Score: 2Etanercept response clusters identified in patients with JIA - 3 year(s) ago
Researchers have found that children and young people with juvenile idiopathic arthritis can be categorized into five different groups according to their response to etanercept treatment.
Source: rheumatology.medicinematters.comCategories: Latest Headlines, RheumatologyTweet-
#EULAR21 news: @sshoopworrall & colleagues have identified #etanercept response clusters in children & young people with JIA https://t.co/1UJbzOsNhR
-
Clinical efficacy and safety of #adalimumab versus #etanercept in #AnkylosingSpondylitis in #Croatia. Check out the results of the multicentre 12-month follow-up study 👉https://t.co/mvOhoKILa9 https://t.co/43ztFQgPWX